Rituximab therapy in patients with refractory dermatomyositis or polymyositis: differential effects in a real-life population.

OBJECTIVES While a double-blind trial has not met its endpoint, rituximab (RTX) is still seen as useful in refractory DM and PM. In this study we analysed the charts of all patients receiving RTX for myositis in our institutions for objective outcome parameters. METHODS In a retrospective way, the charts of all patients with PM or DM who received RTX were analysed for glucocorticoid dose, creatine phosphokinase (CPK) and lung function tests, as well as for serious adverse events. RESULTS A total of 19 patients were identified, 1 of whom died from aspiration pneumonia 3 weeks after the first RTX infusion. The charts of 18 patients (13 PM, 5 DM) could be further analysed. In addition to the fatal pneumonia, six more severe infections were seen. One patient developed hypogammaglobulinaemia. Two patients had mild infusion reactions. Under RTX, both CPK and daily prednisolone dose were reduced by week 18. Six of eight patients with alveolitis improved under RTX. Overall, 9 of 13 PM patients responded. Six of the responders and two patients without documented response, all anti-synthetase syndrome patients, were re-treated. In contrast, all five DM patients responded and none required re-treatment. CONCLUSION In a real-life population of patients with severe, refractory PM or DM, objective improvement was seen in the majority of patients with regard to CPK and lung function tests, and glucocorticoids could be reduced. In contrast to the subgroup with DM, where one cycle of RTX appeared sufficient, patients with anti-synthetase syndromes commonly experienced flares necessitating RTX re-treatment. Infections are of concern.

[1]  H. Rockette,et al.  Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. , 2013, Arthritis and rheumatism.

[2]  D. Furst,et al.  Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients , 2012, Annals of the rheumatic diseases.

[3]  C. Oddis,et al.  Therapeutic advances in myositis , 2012, Current opinion in rheumatology.

[4]  J. Ménard,et al.  Rituximab therapy for refractory interstitial lung disease related to antisynthetase syndrome. , 2012, Respiratory medicine.

[5]  P. V. van Riel,et al.  Rituximab treatment in patients with refractory inflammatory myopathies. , 2011, Rheumatology.

[6]  M. Dougados,et al.  Efficacy and safety of rituximab in the treatment of refractory inflammatory myopathies in adults: results from the AIR registry. , 2011, Rheumatology.

[7]  M. Dalakas.  Inflammatory myopathies: management of steroid resistance. , 2011, Current opinion in neurology.

[8]  C. Bodemer,et al.  Safety and Efficacy of Rituximab in Severe Juvenile Dermatomyositis: Results from 9 Patients from the French Autoimmunity and Rituximab Registry , 2011, The Journal of Rheumatology.

[9]  R. Fischer-Betz,et al.  Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID) , 2011, Arthritis research & therapy.

[10]  A. Mammen,et al.  Rituximab therapy for myopathy associated with anti–signal recognition particle antibodies: A case series , 2010, Arthritis care & research.

[11]  B. Feldman,et al.  Validation of manual muscle testing and a subset of eight muscles for adult and juvenile idiopathic inflammatory myopathies , 2010, Arthritis care & research.

[12]  F. Dammacco,et al.  CD20‐depleting therapy in autoimmune diseases: from basic research to the clinic , 2010, Journal of internal medicine.

[13]  J. Gran,et al.  Rituximab treatment of the anti-synthetase syndrome: a retrospective case series. , 2009, Rheumatology.

[14]  N. McHugh,et al.  Myositis-specific autoantibodies: their clinical and pathogenic significance in disease expression. , 2009, Rheumatology.

[15]  M. Cooper,et al.  Rituximab for the treatment of juvenile dermatomyositis: a report of four pediatric patients. , 2007, Arthritis and rheumatism.

[16]  C. Mok,et al.  Rituximab for refractory polymyositis: an open-label prospective study. , 2007, The Journal of rheumatology.

[17]  M. Genovese,et al.  A pilot trial of rituximab in the treatment of patients with dermatomyositis. , 2007, Archives of dermatology.

[18]  I. Lundberg,et al.  Immune mechanisms in the pathogenesis of idiopathic inflammatory myopathies , 2007, Arthritis research & therapy.

[19]  M. Weinblatt,et al.  Rituximab as therapy for refractory polymyositis and dermatomyositis. , 2006, The Journal of rheumatology.

[20]  T. Levine.  Rituximab in the treatment of dermatomyositis: an open-label pilot study. , 2005, Arthritis and rheumatism.

[21]  D. Isenberg,et al.  Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies. , 2001, Rheumatology.

[22]  D. Isenberg,et al.  Autoantibody profiles in the sera of European patients with myositis , 2001, Annals of the rheumatic diseases.

[23]  M. Dalakas,et al.  A New Approach to the Classification of Idiopathic Inflammatory Myopathy: Myositis‐Specific Autoantibodies Define Useful Homogeneous Patient Groups , 1991, Medicine.

[24]  A. Bohan,et al.  Polymyositis and dermatomyositis (second of two parts). , 1975 .

[25]  H. Prince,et al.  Rituximab for the treatment of the skin manifestations of dermatomyositis: a report of 3 cases. , 2007, Journal of the American Academy of Dermatology.